MétaCan
Menu
Back to cohort
Record W2266260677 · doi:10.1038/sigtrans.2015.2

Intravenous immune globulin suppresses angiogenesis in mice and humans

2016· article· en· W2266260677 on OpenAlexfundno aff
Reo Yasuma, Valeria Cicatiello, Takeshi Mizutani, Laura Tudisco, Young‐Hee Kim, Valeria Tarallo, Sasha Bogdanovich, Yoshio Hirano, Nagaraj Kerur, Shengjian Li, Tetsuhiro Yasuma, Benjamin J. Fowler, Charles B. Wright, Ivana Apicella, Adelaide Greco, Arturo Brunetti, Balamurali K. Ambati, Sevim Barbasso Helmers, Ingrid E. Lundberg, Ondřej Viklický, Jeanette H.W. Leusen, J. Sjef Verbeek, Bradley D. Gelfand, Ana Bastos-Carvalho, Sandro De Falco, Jayakrishna Ambati

Bibliographic record

VenueSignal Transduction and Targeted Therapy · 2016
Typearticle
Languageen
FieldMedicine
TopicMonoclonal and Polyclonal Antibodies Research
Canadian institutionsnot available
FundersNational Center for Research ResourcesNational Institute of General Medical SciencesNational Eye InstituteNational Heart, Lung, and Blood InstituteInstitute of GeneticsNational Institutes of HealthEllison Medical FoundationAmerican Heart AssociationAssociazione Italiana per la Ricerca sul CancroArnold and Mabel Beckman Initiative for Macular ResearchFundação ChampalimaudAlcon JapanMinistério da SaúdeResearch to Prevent BlindnessJohn Templeton FoundationInternational Retinal Research FoundationU.S. Department of Defense
KeywordsMedicineAntibodyImmunologyNeovascularizationAngiogenesisImmune systemPolyclonal antibodiesPotencyPharmacologyDrugCancer researchIn vitroBiology

Abstract

fetched live from OpenAlex

Human intravenous immune globulin (IVIg), a purified IgG fraction composed of ~ 60% IgG1 and obtained from the pooled plasma of thousands of donors, is clinically used for a wide range of diseases. The biological actions of IVIg are incompletely understood and have been attributed both to the polyclonal antibodies therein and also to their IgG (IgG) Fc regions. Recently, we demonstrated that multiple therapeutic human IgG1 antibodies suppress angiogenesis in a target-independent manner via FcγRI, a high-affinity receptor for IgG1. Here we show that IVIg possesses similar anti-angiogenic activity and inhibited blood vessel growth in five different mouse models of prevalent human diseases, namely, neovascular age-related macular degeneration, corneal neovascularization, colorectal cancer, fibrosarcoma and peripheral arterial ischemic disease. Angioinhibition was mediated by the Fc region of IVIg, required FcγRI and had similar potency in transgenic mice expressing human FcγRs. Finally, IVIg therapy administered to humans for the treatment of inflammatory or autoimmune diseases reduced kidney and muscle blood vessel densities. These data place IVIg, an agent approved by the US Food and Drug Administration, as a novel angioinhibitory drug in doses that are currently administered in the clinical setting. In addition, they raise the possibility of an unintended effect of IVIg on blood vessels.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.005

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.021
GPT teacher head0.272
Teacher spread0.251 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations27
Published2016
Admission routes1
Has abstractyes

Explore more

Same venueSignal Transduction and Targeted TherapySame topicMonoclonal and Polyclonal Antibodies ResearchFrench-language works237,207